Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT)

Paul G Richardson,Andrzej Jakubowiak,Nizar J Bahlis,David S Siegel,Christine I Chen,Min Chen,Mohamed Zaki,Gail Larkins,Kenneth C Anderson

doi:10.1182/blood.v120.21.4053.4053

Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT)

Paul G Richardson, Andrzej Jakubowiak + Show 7 more

https://doi.org/10.1182/blood.v120.21.4053.4053

Copy DOI

Journal: Blood	Publication Date: Nov 16, 2012
Citations: 13

Affiliation: Dana-Farber Cancer Institute, University of Chicago Medical Center, University of Calgary, Hackensack University Medical Center, Princess Margaret Cancer Centre, Emory University

#Mos For Pts #High-risk Cytogenetic Profiles + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT)

Full Text